Compare Stocks → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CHEKNYSE:RMEDNASDAQ:XBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHEKCheck-Cap$2.29$2.35$1.78▼$4.63$13.40M0.44159,833 shs8,917 shsRMEDRa Medical Systems$0.73$0.52▼$11.14$3.19M-0.03197,480 shs77,500 shsXBIOXenetic Biosciences$4.05+3.8%$4.03$2.87▼$5.97$6.24M2.375,381 shs3,465 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHEKCheck-Cap-0.22%+0.88%+4.09%+17.44%+28.65%RMEDRa Medical Systems0.00%0.00%0.00%0.00%-43.43%XBIOXenetic Biosciences+3.91%+3.91%-5.09%-0.91%+27.04%Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHEKCheck-CapN/AN/AN/AN/AN/AN/AN/AN/ARMEDRa Medical SystemsN/AN/AN/AN/AN/AN/AN/AN/AXBIOXenetic Biosciences1.0043 of 5 stars0.05.00.00.02.90.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHEKCheck-Cap2.00HoldN/AN/ARMEDRa Medical SystemsN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHEKCheck-CapN/AN/AN/AN/A$4.05 per shareN/ARMEDRa Medical Systems$10K0.00N/AN/A$4.29 per share0.00XBIOXenetic Biosciences$2.54M2.46N/AN/A$6.36 per share0.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHEKCheck-Cap-$17.57M-$3.00N/A∞N/AN/A-54.79%-50.21%6/6/2024 (Estimated)RMEDRa Medical Systems-$26.86M-$92.36N/AN/AN/AN/A-496.57%-344.49%N/AXBIOXenetic Biosciences-$4.14M-$2.93N/AN/AN/A-182.99%-43.40%-40.03%8/9/2024 (Estimated)Latest CHEK, N4P, XBIO, RMED, and NC6 EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q4 2023CHEKCheck-CapN/A-$0.62-$0.62-$0.62N/AN/A5/9/2024Q1 2024XBIOXenetic Biosciences-$0.79-$0.78+$0.01-$0.78$0.65 million$0.51 million3/21/2024Q4 2023XBIOXenetic Biosciences-$0.87-$0.77+$0.10-$0.77$0.68 million$0.67 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHEKCheck-CapN/AN/AN/AN/AN/ARMEDRa Medical SystemsN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHEKCheck-CapN/A18.6918.69RMEDRa Medical SystemsN/A2.862.85XBIOXenetic BiosciencesN/A11.7011.70OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHEKCheck-Cap1.07%RMEDRa Medical Systems11.00%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipCHEKCheck-Cap0.48%RMEDRa Medical Systems18.62%XBIOXenetic Biosciences9.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCHEKCheck-Cap855.85 million5.82 millionNot OptionableRMEDRa Medical Systems145.37 million4.37 millionNot OptionableXBIOXenetic Biosciences41.54 million1.40 millionNot OptionableCHEK, N4P, XBIO, RMED, and NC6 HeadlinesRecent News About These CompaniesMay 29, 2024 | americanbankingnews.comShort Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 39.7%May 9, 2024 | zacks.comXenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue EstimatesApril 10, 2024 | investing.comXenetic Biosciences Inc (XBIO)March 24, 2024 | finance.yahoo.comXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 22, 2024 | baystreet.caXenetic Dips on Full-Year ResultsMarch 22, 2024 | msn.comXenetic Biosciences reports FY resultsMarch 22, 2024 | accesswire.comXenetic Biosciences, Inc. Reports Full Year 2023 Financial ResultsJanuary 18, 2024 | msn.comXenetic to advance DNase programme with UVA partnershipJanuary 4, 2024 | morningstar.comXenetic Biosciences Inc XBIODecember 11, 2023 | benzinga.comXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastNovember 30, 2023 | finance.yahoo.comMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO CompensationNovember 10, 2023 | benzinga.comXenetic Biosciences: Q3 Earnings InsightsNovember 10, 2023 | washingtonpost.comMediciNova: Q3 Earnings SnapshotOctober 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceJuly 13, 2023 | msn.comXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?May 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 5, 2023 | morningstar.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarMay 4, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentMay 3, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Read an Earnings Report | Step by Step Guide with TipsMay 8, 2024 9:00 AMView How to Read an Earnings Report | Step by Step Guide with TipsWhat Is Risk Tolerance & Why Is It Important?June 3, 2024 10:30 AMView What Is Risk Tolerance & Why Is It Important?Garmin Navigates to New Highs Driven By Wearables TrendMay 7, 2024 12:52 PMView Garmin Navigates to New Highs Driven By Wearables TrendDetermining Your Risk Tolerance - A Comprehensive GuideMay 29, 2024 10:28 AMView Determining Your Risk Tolerance - A Comprehensive GuideLowe’s Companies Tracking to New Highs in 2024May 21, 2024 9:15 AMView Lowe’s Companies Tracking to New Highs in 2024All HeadlinesCompany DescriptionsCheck-CapNASDAQ:CHEKCheck-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.Ra Medical SystemsNYSE:RMEDRa Medical Systems, Inc develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. Ra Medical Systems, Inc is based in Fort Mill, South Carolina.Xenetic BiosciencesNASDAQ:XBIOXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.